Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:OLMA NASDAQ:RXRX NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$96.79-0.7%$82.71$52.50▼$99.50$2.12B0.63380,949 shs346,251 shsOLMAOlema Pharmaceuticals$8.17-4.0%$5.80$2.86▼$13.93$584.08M1.921.11 million shs1.68 million shsRXRXRecursion Pharmaceuticals$4.91-0.4%$5.29$3.79▼$12.36$2.14B0.9116.49 million shs53.03 million shsTVTXTravere Therapeutics$24.85+2.7%$18.50$12.91▼$28.69$2.16B0.792.74 million shs4.42 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+2.22%-1.27%+8.17%+48.69%+59.67%OLMAOlema Pharmaceuticals+9.81%+6.38%+56.72%+106.05%-33.57%RXRXRecursion Pharmaceuticals+4.67%+1.65%-3.14%-1.99%-28.65%TVTXTravere Therapeutics+2.28%-3.24%+37.21%+69.04%+68.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$96.79-0.7%$82.71$52.50▼$99.50$2.12B0.63380,949 shs346,251 shsOLMAOlema Pharmaceuticals$8.17-4.0%$5.80$2.86▼$13.93$584.08M1.921.11 million shs1.68 million shsRXRXRecursion Pharmaceuticals$4.91-0.4%$5.29$3.79▼$12.36$2.14B0.9116.49 million shs53.03 million shsTVTXTravere Therapeutics$24.85+2.7%$18.50$12.91▼$28.69$2.16B0.792.74 million shs4.42 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+2.22%-1.27%+8.17%+48.69%+59.67%OLMAOlema Pharmaceuticals+9.81%+6.38%+56.72%+106.05%-33.57%RXRXRecursion Pharmaceuticals+4.67%+1.65%-3.14%-1.99%-28.65%TVTXTravere Therapeutics+2.28%-3.24%+37.21%+69.04%+68.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.11Buy$93.00-3.92% DownsideOLMAOlema Pharmaceuticals 2.83Moderate Buy$24.00193.76% UpsideRXRXRecursion Pharmaceuticals 2.40Hold$7.2547.66% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$34.2037.63% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, ANIP, RXRX, and TVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/19/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.009/17/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$93.00 ➝ $121.009/12/2025TVTXTravere TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$20.00 ➝ $25.009/11/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/11/2025TVTXTravere TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$27.00 ➝ $35.009/10/2025TVTXTravere TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.009/10/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.009/9/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/8/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$86.00 ➝ $114.009/3/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.009/3/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M3.42$7.54 per share12.83$19.11 per share5.06OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/ARXRXRecursion Pharmaceuticals$58.84M36.23N/AN/A$2.61 per share1.88TVTXTravere Therapeutics$233.18M9.50N/AN/A$0.76 per share32.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$0.77N/A22.99N/A-1.37%25.03%8.00%11/14/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)Latest OLMA, ANIP, RXRX, and TVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/6/2025Q2 2025TVTXTravere Therapeutics-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.392.541.96OLMAOlema Pharmaceuticals0.0111.0911.09RXRXRecursion Pharmaceuticals0.023.583.58TVTXTravere Therapeutics9.502.001.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%OLMAOlema Pharmaceuticals91.78%RXRXRecursion Pharmaceuticals89.06%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%OLMAOlema Pharmaceuticals16.36%RXRXRecursion Pharmaceuticals8.43%TVTXTravere Therapeutics4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.70 million19.29 millionOptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableTVTXTravere Therapeutics46089.14 million85.40 millionOptionableOLMA, ANIP, RXRX, and TVTX HeadlinesRecent News About These CompaniesTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $25.00September 14, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Given New $25.00 Price Target at Stifel NicolausSeptember 14, 2025 | americanbankingnews.comTravere Therapeutics, Inc. $TVTX Shares Sold by AQR Capital Management LLCSeptember 14, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Shares Down 4.8% - Should You Sell?September 13, 2025 | marketbeat.comWells Fargo & Company Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13, 2025 | marketbeat.comWoodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTXSeptember 13, 2025 | marketbeat.comWells Fargo & Company Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13, 2025 | americanbankingnews.comTravere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGSSeptember 12, 2025 | seekingalpha.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High - Here's What HappenedSeptember 12, 2025 | marketbeat.comTVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDASeptember 11, 2025 | zacks.comTravere Therapeutics price target raised to $35 from $27 at Wells FargoSeptember 11, 2025 | msn.comTravere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate SubsideSeptember 11, 2025 | insidermonkey.comStrength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?September 11, 2025 | zacks.comTravere rises as FDA says no AdCom required for Filspari label expansionSeptember 10, 2025 | msn.comTravere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug ApplicationSeptember 10, 2025 | msn.comTravere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical ResultsSeptember 10, 2025 | finance.yahoo.comTravere: No AdCom, No Problem - Targeting Big Revenues With FSGS ApprovalSeptember 10, 2025 | seekingalpha.comTraders Purchase High Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX)September 10, 2025 | marketbeat.comWhy Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year HighSeptember 10, 2025 | investors.comTravere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGSSeptember 10, 2025 | businesswire.comPolar Asset Management Partners Inc. Acquires New Position in Travere Therapeutics, Inc. $TVTXSeptember 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOLMA, ANIP, RXRX, and TVTX Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$96.79 -0.69 (-0.71%) Closing price 04:00 PM EasternExtended Trading$96.80 +0.01 (+0.01%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Olema Pharmaceuticals NASDAQ:OLMA$8.17 -0.34 (-4.00%) Closing price 04:00 PM EasternExtended Trading$8.34 +0.17 (+2.08%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Recursion Pharmaceuticals NASDAQ:RXRX$4.91 -0.02 (-0.41%) Closing price 04:00 PM EasternExtended Trading$4.93 +0.02 (+0.41%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Travere Therapeutics NASDAQ:TVTX$24.85 +0.66 (+2.73%) Closing price 04:00 PM EasternExtended Trading$24.84 -0.02 (-0.06%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Azure Leads While AI Excitement Fuels Microsoft Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
